查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1827373

分子诊断市场（按产品、技术、检体类型、测试类型、应用和最终用户划分）—2025-2032 年全球预测

Molecular Diagnostics Market by Offering, Technology, Specimen Type, Test Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年分子诊断市场规模将成长至 816 亿美元，复合年增长率为 14.29%。

主要市场统计数据
基准年2024年 280.2亿美元
预计2025年 318.6亿美元
预测年份：2032年 816亿美元
复合年增长率（%） 14.29%

探索分子诊断市场基础：创新、临床驱动因素和医疗保健服务的新机会

分子诊断技术凭藉其在基因和分子层面上检测、表征和监测疾病的卓越精确度，已成为现代医疗保健服务的基石。该领域涵盖了广泛的检测方法和分析平台，旨在识别特定的基因突变、病原体和生物标记物，从而实现个人化治疗策略并改善患者预后。检测灵敏度的提高，加上定序和先进影像技术成本的下降，正促使分子诊断工具在临床实验室、研究机构和照护现场中广泛应用。

次世代定序、增强型聚合酵素链锁反应和质谱技术的突破推动了检测能力的扩展，同时法律规范也进行了调整，以加快创新诊断方法的核准。实验室基础设施和数位化整合的同步投资正在增强数据系统的互通性，促进患者资讯的无缝流动和快速的临床决策。此外，诊断学和治疗学的融合（通常称为治疗诊断学）正将分子检测置于标靶治疗通讯协定的核心地位。

展望未来，不断变化的监管格局、报销策略和临床需求之间的相互作用将决定市场的成长轨迹。相关人员必须克服复杂的营运挑战，包括扩充性、品管和供应链弹性，同时利用癌症、感染疾病和基因筛检等新兴应用带来的机会。分子诊断的整体发展动能也显示了其在重塑患者照护模式和推动精准医疗新前沿方面发挥的关键作用。

从个人化医疗的整合到临床测试的监管演变和技术融合，揭示重新定义分子诊断的颠覆性转变

在检测技术、数据分析和治疗整合的推动下，分子诊断领域正在经历翻天覆地的变化。随着基因组分析和生物标记引导治疗在肿瘤学和罕见疾病管理中变得至关重要，个人化医疗正从理论愿景走向现实。数位病理学和人工智慧平台简化了影像解读和预测建模，提高了诊断准确性，进一步促进了这项变革。

为了应对这一转变，监管机构正在製定适应性路径，旨在加快高影响力检测的市场准入，但同时，对临床验证和上市后监管的审查也日益严格。同时，成本控制压力和对真实世界证据的需求迫使製造商透过基于结果的研究来证明其价值。 COVID-19疫情证明了分子诊断开发商在扩大高通量检测生产方面的灵活性，并成为公私合作应对紧迫卫生危机的催化剂。

因此，相关人员正在见证去中心化趋势与中心化检测能力的融合。 POC平台日趋成熟，提供快速的周转时间和易用性，而中心化实验室则不断突破多重侦测和超高通量定序的界限。这种二元性将催生一个更强大的诊断生态系统，既能满足常规筛检需求，又能满足大规模监测需求。因此，市场相关人员正在重新评估其产品组合，并建立策略联盟，以应对这些颠覆性趋势，并确保其在快速变化的环境中保持韧性和相关性。

美国新关税政策对分子诊断供应链的综合影响及2025年战略製造业重组评估

预计到2025年，美国关税政策的变化将对分子诊断产业的成本结构和供应链策略产生重大影响。随着进口试剂、设备和辅助零件关税的提案，製造商和实验室正在为可能转嫁给医疗服务提供者和患者的投入成本增加做准备。这种情况凸显了策略性采购和供应基础多元化的必要性，以减轻关税带来的价格压力。

为此，一些仪器製造商正在探索本地化组装业务或建立国内试剂生产设施等方案。虽然这些措施可以减轻关税负担，但可能需要大量的资本投入和较长的时间才能达到法规合规要求。同时，诊断开发商正在积极与经销商谈判，以达成长期供应协议，采用双重采购安排，并探索关键材料的近岸外包机会。

这些措施的累积效应可能会重塑竞争动态，拥有强大垂直整合能力和供应链敏捷性的公司将获得成本优势。同时，规模较小的公司可能难以消化上调的关税，同时又不损害盈利或将成本转嫁给最终用户。政策的不确定性进一步加剧了投资决策的复杂性，迫使相关人员模拟各种关税情境并建立紧急框架。在这种情况下，从原料供应商到最终用户实验室的整个价值链的协作对于维持尖端分子诊断解决方案的可近性和确保患者照护的连续性至关重要。

深入研究所提供的技术、检体类型、测试格式、应用领域和最终用户概况，以推动分子诊断的策略性细分

仔细观察市场就会发现，每个细分市场都提供独特的价值主张：仪器提供硬体支撑，套件和试剂盒提供生化特异性，软体和服务支援数据管理和提案分析。技术范围广泛，包括用于染色体和基因图谱的萤光杂合反应、用于蛋白质组分析的质谱技术、用于平行标靶筛检的微阵列分析技术、EXOME、RNA、标靶和全基因组的次世代定序，以及涵盖数位、多重和即时变异的聚合酵素链锁反应平台。

检体类型的多样性反映了分子检测的多样性，从血液和脑脊髓液到鼻咽拭子、唾液、粪便、组织切片检查和尿液，每种检测方法都有不同的预处理和分析要求。检测类型的分类凸显了实验室模式与中央、医院和独立实验室基础设施以及针对快速、分散诊断最佳化的即时诊断系统的共存。应用领域包括提供携带者、诊断和预测服务的基因检测；细菌、寄生虫和病毒病原体的感染疾病检测；利用液态切片、微量残存疾病评估和组织切片检查进行肿瘤监测；以及侵入性和非侵入性形式的产前检测。

最终用户范围广泛，从引领检测方法开发的学术研究机构，到专注于高通量检测的诊断实验室，再到为第一线患者提供医疗服务的医院和诊所。这些细分市场拥有不同的资本强度、法规要求和应用曲线。了解产品、技术、检体类型、检测格式、应用领域和最终用户特征之间的相互关係，有助于相关人员协调策略倡议和产品系列，以应对不断变化的临床需求和市场动态。

市场成熟度投资趋势凸显了亚太地区分子诊断采用和医疗保健基础设施的区域差异

美洲、欧洲、中东和非洲以及亚太地区多样化的经济、监管和医疗基础设施因素共同塑造市场动态。在美洲，完善的报销环境和大型诊断公司的集中度推动着先进检测方法的快速普及，而官民合作关係则加速了液态切片和伴随诊断等领域的创新。北美在监管透明度方面仍处于领先地位，各机构正在製定适应性核准途径，并鼓励整合真实世界数据。

欧洲、中东和非洲的成熟度水准参差不齐。西欧拥有统一的法律规范，并为精准医疗计画提供了充足的资金；而中东地区则正在对医疗基础设施和分子检测能力进行策略性投资。感染疾病监测计画正在推动一些非洲市场的成长，但实验室能力和供应链可靠性方面仍面临挑战。跨国合作和能力建构工作正在帮助填补空白，并扩大服务欠缺地区的检测管道。

亚太地区的特点是国内诊断製造商的快速扩张以及政府主导的加强基因组医学的努力。中国、印度和日本等国家正在扩大定序中心和就地检验网络，以支持大规模筛检和公共卫生监测。这些市场的监管机构正日益与国际标准接轨，从而促进高影响力检测方法的快速核准。总而言之，这种区域多样性凸显了量身定制的参与策略和以本地为重点的伙伴关係关係的重要性，以充分利用不同的成长轨迹和医疗保健重点。

主要分子诊断主要企业的概况、影响市场动态的竞争策略、创新伙伴关係和研发投资

主要企业正透过对次世代定序能力的定向投资、试剂供应的策略联盟以及人工智慧解读工具的整合来脱颖而出。一些公司建立了专业中心，以加速检测开发并简化临床验证流程，而其他公司则透过併购来扩大产品系列併进入新兴市场。透过与製药公司的合作，伴随诊断在临床试验设计和治疗决策中发挥越来越重要的作用。

专注于数位PCR和快速照护现场平台等利基应用的中阶市场公司也在不断创新。这些公司注重敏捷性，利用模组化仪器架构和云端基础的分析流程来缩短部署时间并实现远端监控。此外，诊断开发商和学术研究机构之间的合作正在开发针对罕见疾病和新型癌症生物标记的尖端检测方法，这些合作通常由共同开发契约支持，这些协议既共用技术专长，也共担商业化风险。

因此，竞争格局正朝着生态系统模式发展，产品供应商、软体供应商和服务实验室构成一个互联互通的网路。这种方法增强了客户的端到端解决方案，提供了从样本采集到数据报告的无缝工作流程。能够提供全面的产品、良好的监管记录和可扩展的生产能力的公司最有可能获得与医疗保健系统的长期合同，并在这个充满活力的市场中保持优势。

为产业领导者提供可行的策略建议，以利用新兴的分子诊断机会，同时降低风险并简化市场进入流程

为了在不断变化的分子诊断环境中取得成功，产业领导者应优先考虑策略性投资组合多元化，拓展液态切片和数位PCR等高成长技术领域。开发适用于集中式实验室工作流程和照护现场应用的模组化平台，将增强市场覆盖率和韧性。同时，与试剂供应商和学术伙伴关係合作可以降低供应链风险并加快检测检验。

领导者还需要深化与付款者和监管机构的合作，建立基于价值的报销框架，奖励以诊断主导的治疗途径。透过纵向研究和病患登记系统投资于现实世界证据的生成，将增强经济价值提案。在营运方面，透过近岸外包和双重采购安排优化製造布局，可以抵消潜在关税的影响，并确保关键的供应连续性。

此外，将人工智慧和机器学习融入您的数据分析流程，可以为您提供切实可行的洞察和预测能力，从而脱颖而出。采用数位连线来支援远距离诊断和远端医疗服务，可以帮助您满足医疗服务提供者和患者不断变化的需求。最后，在组织内培育持续学习和跨职能协作的文化，可以促进创新，并使其能够快速适应新的市场趋势和监管变化。

全面的调查方法详细说明了资料收集、主要和次要资讯检验过程和分析框架，为分子诊断洞察奠定了基础。

调查方法采用严格的多阶段方法，以确保获得全面且准确的洞察。主要研究透过对关键相关人员（包括实验室主任、临床研究人员和监管专家）的深入访谈进行。这些质性研究也辅以对医院和独立检测机构决策者的结构化调查，以收集关于技术采用、营运挑战和成长重点的第一手观点。

我们的二次研究系统性地回顾了同行评审的科学文献、监管文件和行业报告，以便将我们的主要研究结果纳入更广泛的市场和政策趋势中。公司新闻稿、专利申请和财务揭露提供了有关竞争策略和创新轨蹟的详细资讯。我们使用交叉验证技术对资料点进行三角测量，以识别和协调不一致之处，确保研究的稳健性和可靠性。

此分析框架融合了定性主题分析和定量趋势建模。細項分析透过与专家的迭代回馈循环进行完善，使市场分类与实际临床工作流程一致。所有研究结果均经过严格的同行评审和品质保证检查，以检验资料输入的完整性和解释性结论的有效性。此调查方法的严谨性确保了报告中提出的战略建议和可操作情报的可信度。

分子诊断市场趋势创新整合关键见解和策略要点，总结永续成长和復苏的挑战和途径

摘要：在技术创新、法规不断演变和临床应用不断拓展的推动下，分子诊断市场正处于转型成长的风口浪尖。产品、技术、检体类型、检测方式、应用和最终用户的策略性细分揭示了一个复杂的生态系统，表明有针对性的投资和合作伙伴关係关係对于持续成功至关重要。区域动态进一步凸显了采用客製化方法来应对多样化医疗基础设施和政策环境的必要性。

竞争优势取决于企业能否整合高阶分析技术，维持供应链韧性，并透过坚实的临床和经济证据展现实际的价值。上市公司若优先考虑敏捷性，并在集中式实验室能力与分散式即时诊断 (POC) 解决方案之间取得平衡，将更有能力满足常规诊断需求和公共卫生需求。此外，积极与监管机构和付款方沟通将有助于简化核准，并建立有利的报销途径。

最终，它需要创新、协作和策略远见的整合。凭藉对市场趋势的实际洞察，相关人员可以预测变化、降低风险并抓住新机会。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 透过整合人工智慧驱动的分析平台转变高通量分子诊断工作流程
  • 分散式次世代定序面板的引入使远距医疗环境中的精准医疗成为可能
  • 用于非侵入性癌症筛检和监测的多重液态生物检体检测的出现
  • 伴随诊断的监管核准不断增加，促进了全球个人化肿瘤治疗方案的出现
  • 扩大基于 CRISPR 的即时诊断检测的使用将实现快速病原体检测
  • 微流体实验室晶片平台的进步减少了分子检测的测试量和周转时间
  • 越来越多地采用数位 PCR 技术来提高罕见突变检测的灵敏度和定量准确性

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章分子诊断市场（依产品提供）

  • 装置
  • 试剂和套件
  • 软体和服务

第九章分子诊断市场（按技术）

  • 萤光原位杂合反应
  • 质谱法
  • 微阵列分析
  • 次世代定序
    • EXOME定序
    • RNA定序
    • 标靶定序
    • 全基因组序列分析
  • 聚合酵素链锁反应
    • 数位PCR
    • 多重PCR
    • 即时PCR

第 10 章分子诊断市场（依检体类型）

  • 血
  • 脑脊髓液（CSF）
  • 鼻/咽拭子
  • 唾液
  • 航班
  • 组织切片检查
  • 尿

第 11 章分子诊断市场（依测试类型）

  • 基于实验室
    • 中央研究院
    • 医院检查室
    • 独立实验室
  • 照护现场

第十二章分子诊断市场（按应用）

  • 基因检测
    • 职业测试
    • 诊断测试
    • 预测测试
  • 感染疾病
    • 细菌
    • 寄生虫
    • 病毒性的
  • 肿瘤学
    • 液态生物检体
    • 微量残存疾病
    • 组织切片检查
  • 产前检查
    • 侵入性
    • 非侵入性

第 13 章 分子诊断市场（依最终使用者）

  • 学术研究机构
  • 诊断实验室
  • 医院和诊所

第十四章分子诊断市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章分子诊断市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国分子诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories Inc.
    • ADT Biotech Co., Ltd.
    • AstraZeneca plc
    • Becton, Dickinson, and Company
    • Bio-Rad Laboratories, Inc.
    • Biocartis Group NV
    • bioMerieux SA
    • Castle Biosciences, Inc.
    • Danaher Corporation
    • Diasorin Sp,A.
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche AG
    • Grifols SA
    • Guardant Health, Inc.
    • Hologic, Inc.
    • Illumina, Inc.
    • Laboratory Corporation of America Holdings
    • Myriad Genetics, Inc.
    • Oxford Nanopore Technologies
    • QIAGEN NV
    • Siemens Healthineers AG
    • Source BioScience
    • Sysmex Corporation by Oxford Gene Technology
    • Thermo Fisher Scientific Inc.
Product Code: MRR-434CCDA04D46

The Molecular Diagnostics Market is projected to grow by USD 81.60 billion at a CAGR of 14.29% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 28.02 billion
Estimated Year [2025] USD 31.86 billion
Forecast Year [2032] USD 81.60 billion
CAGR (%) 14.29%

Exploring the Molecular Diagnostics Market's Foundations Technological Innovations Clinical Drivers and Emerging Opportunities in Healthcare Delivery

Molecular diagnostics has emerged as a cornerstone of modern healthcare delivery by offering unprecedented precision in detecting, characterizing, and monitoring disease at the genetic and molecular levels. This field encompasses a broad array of assays and analytical platforms designed to identify specific genetic mutations, pathogens, and biomarkers, thereby enabling personalized treatment strategies and improving patient outcomes. Progress in assay sensitivity, coupled with the declining cost of sequencing and advanced imaging, has fueled widespread adoption of molecular diagnostic tools across clinical laboratories, research institutions, and point-of-care settings.

Technological breakthroughs in next-generation sequencing, polymerase chain reaction enhancements, and mass spectrometry have catalyzed the expansion of testing capabilities, while regulatory frameworks have adapted to accelerate approvals for innovative diagnostics. Concurrent investments in laboratory infrastructure and digital integration are reinforcing the interoperability of data systems, facilitating seamless flow of patient information and rapid clinical decision-making. Moreover, the convergence of diagnostics and therapeutics, often referred to as theranostics, positions molecular assays at the heart of targeted treatment protocols.

Looking ahead, the interplay of evolving regulatory landscapes, reimbursement strategies, and shifting clinical needs will determine the trajectory of market growth. Stakeholders must navigate complex operational challenges, including scalability, quality control, and supply chain resilience, while capitalizing on opportunities presented by emerging applications in oncology, infectious diseases, and genetic screening. The collective momentum behind molecular diagnostics underscores its critical role in reshaping patient care paradigms and driving the next frontier of precision medicine.

Unveiling the Disruptive Shifts Redefining Molecular Diagnostics from Personalized Medicine Integration to Regulatory Evolution and Technological Convergence in Clinical Testing

The molecular diagnostics landscape is undergoing a seismic transformation driven by advancements in assay technologies, data analytics, and therapeutic integration. Personalized medicine has shifted from theoretical promise to tangible reality as genomic profiling and biomarker-guided therapies become integral to oncology and rare disease management. This evolution is further amplified by digital pathology and artificial intelligence platforms that streamline image interpretation and predictive modeling, enhancing diagnostic precision.

Regulatory authorities are responding to these shifts with adaptive pathways designed to expedite market entry for high-impact assays, though this progress is accompanied by heightened scrutiny on clinical validation and post-market surveillance. At the same time, cost-containment pressures and demands for real-world evidence are compelling manufacturers to demonstrate value through outcome-based studies. The COVID-19 pandemic served as a catalyst, proving the agility of molecular diagnostic developers in scaling production of high-throughput tests and fostering public-private collaborations to address emergent health crises.

As a result, stakeholders are witnessing a convergence of decentralization trends and centralized laboratory capabilities. Point-of-care platforms have matured, offering rapid turnaround times and ease of use, while centralized labs continue to push the boundaries of multiplexed assays and ultra-high-throughput sequencing. This duality enables a more robust diagnostic ecosystem capable of responding to both routine screening needs and large-scale surveillance demands. Consequently, market players are reevaluating their portfolios and forging strategic alliances to align with these disruptive currents, ensuring resilience and relevance in a rapidly evolving environment.

Assessing the Comprehensive Effects of New United States Tariff Policies on Molecular Diagnostics Supply Chains Costs and Strategic Manufacturing Realignments by 2025

Anticipated changes to United States tariff policies by 2025 are poised to exert a profound influence on the molecular diagnostics industry's cost structures and supply chain strategies. With proposals to levy higher duties on imported reagents, instrumentation and ancillary components, manufacturers and laboratories brace for increased input costs that could be passed downstream to healthcare providers and patients. This scenario underscores the need for strategic sourcing and supply base diversification to mitigate exposure to tariff-induced price pressures.

In response, some instrument producers are examining options to localize assembly operations or to establish captive reagent manufacturing facilities within domestic borders. Such initiatives may alleviate tariff burdens but could entail significant capital investment and extended timelines to achieve regulatory compliance. Simultaneously, diagnostic developers are engaging in proactive negotiations with distributors to secure long-term supply contracts, adopting dual sourcing agreements and exploring nearshoring opportunities for critical materials.

The cumulative effect of these measures will reshape competitive dynamics as companies with robust vertical integration and supply chain agility gain a cost advantage. Meanwhile, smaller firms may struggle to absorb elevated duties without compromising profitability or passing costs to end users. Policy uncertainty further complicates investment decisions, compelling stakeholders to model various tariff scenarios and to establish contingency frameworks. In this climate, collaboration across the value chain-from raw material suppliers to end-user laboratories-will be essential to preserve access to cutting-edge molecular diagnostic solutions and to maintain continuity of patient care.

Deep Dive into Offerings Technologies Specimen Types Test Formats Application Areas and End User Profiles Driving Strategic Segmentation in Molecular Diagnostics

A nuanced exploration of the market reveals that each offering segment contributes unique value propositions, with instruments providing the hardware backbone, reagents and kits delivering the biochemical specificity, and software and services enabling data management and interpretive analytics. The technology landscape spans fluorescence in situ hybridization for chromosomal and gene mapping, mass spectrometry for proteomic analysis, microarray assays for parallel target screening, next-generation sequencing in its exome, RNA, targeted and whole-genome modalities, and polymerase chain reaction platforms encompassing digital, multiplex and real-time variants.

Specimen type diversity reflects the versatility of molecular assays, from blood and cerebrospinal fluid to nasal and throat swabs, saliva, stool, tissue biopsies and urine, each presenting distinct preprocessing and analytical requirements. Test type categorization underscores the coexistence of laboratory-based models-with central, hospital and independent lab infrastructures-and point-of-care systems optimized for rapid, decentralized diagnostics. Application areas span genetic testing through carrier, diagnostic and predictive services; infectious disease detection of bacterial, parasitic and viral pathogens; oncology monitoring via liquid biopsy, minimal residual disease assessment and tissue biopsy; and prenatal testing in invasive and noninvasive formats.

End users range from academic and research institutes pioneering assay development, to diagnostic laboratories specializing in high-throughput testing, and hospitals and clinics delivering frontline patient services. These segments exhibit varying capital intensity, regulatory demands and adoption curves. By understanding the interplay among offerings, technologies, specimen types, test formats, application areas and end-user profiles, stakeholders can tailor strategic initiatives and product portfolios to address evolving clinical needs and market dynamics.

Illuminating Regional Variations in Molecular Diagnostics Adoption Market Maturation Investment Trends and Healthcare Infrastructure Across Americas EMEA and Asia Pacific

Regional market dynamics are shaped by diverse economic, regulatory and healthcare infrastructure factors across the Americas, Europe, Middle East and Africa, and Asia-Pacific. In the Americas, a well-established reimbursement environment and concentration of leading diagnostic companies foster rapid adoption of advanced assays, while public-private partnerships accelerate innovation in areas such as liquid biopsy and companion diagnostics. North America remains a bellwether for regulatory clarity, with agencies pioneering adaptive approval pathways and encouraging real-world data integration.

Europe, the Middle East and Africa collectively present a mosaic of maturity levels. Western Europe benefits from harmonized regulatory frameworks and robust funding for precision medicine initiatives, whereas the Middle East is witnessing strategic investments in healthcare infrastructure and molecular testing capabilities. In select African markets, growth is driven by infectious disease surveillance programs, yet challenges persist around laboratory capacity and supply chain reliability. Cross-border collaborations and capacity-building efforts are helping to bridge gaps and to expand testing accessibility in underserved regions.

The Asia-Pacific region is characterized by rapid expansion of domestic diagnostics players and government-led initiatives to bolster genomic medicine. Countries such as China, India and Japan are scaling up sequencing centers and point-of-care testing networks to support large-scale screening and public health monitoring. Regulatory authorities in these markets are increasingly aligning with international standards, facilitating expedited approvals for high-impact assays. Collectively, this regional diversity underscores the importance of tailored entry strategies and localized partnerships to capitalize on varying growth trajectories and healthcare priorities.

Profiling Leading Molecular Diagnostics Companies Highlighting Competitive Strategies Innovations Partnerships and R&D Investments Shaping Market Leadership Dynamics

Leading companies in molecular diagnostics are distinguishing themselves through targeted investments in next-generation sequencing capabilities, strategic alliances for reagent supply and the integration of AI-driven interpretive tools. Some have established dedicated centers of excellence to accelerate assay development and to streamline clinical validation, while others pursue mergers and acquisitions to broaden their product portfolios and to gain access to emerging markets. Collaborative ventures with pharmaceutical firms are amplifying the role of companion diagnostics in clinical trial design and therapeutic decision-making.

Innovation is also thriving among mid-sized organizations that specialize in niche applications such as digital PCR or rapid point-of-care platforms. These players focus on agility, leveraging modular instrument architectures and cloud-based analytic pipelines to reduce deployment time and to enable remote monitoring. Furthermore, partnerships between diagnostic developers and academic research institutes are producing cutting-edge assays for rare diseases and novel oncology biomarkers, often underpinned by co-development agreements that share both technical expertise and commercialization risk.

As a result, the competitive landscape is evolving toward an ecosystem model in which product vendors, software providers and service laboratories form interconnected networks. This approach enhances end-to-end solutions for customers, offering seamless workflows from sample collection to data reporting. Companies that can demonstrate comprehensive offerings, strong regulatory track records and scalable manufacturing capabilities are best positioned to secure long-term contracts with healthcare systems and to maintain a leading edge in this dynamic market.

Actionable Strategic Recommendations for Industry Leaders to Capitalize on Emerging Molecular Diagnostics Opportunities While Mitigating Risks and Streamlining Market Entry

To thrive in the shifting molecular diagnostics environment, industry leaders should prioritize strategic portfolio diversification by expanding into high-growth technology areas such as liquid biopsy and digital PCR. Developing modular platforms that accommodate both centralized laboratory workflows and point-of-care applications will enhance market reach and resilience. Concurrently, forging partnerships with reagent suppliers and academic institutions can mitigate supply chain risks and accelerate assay validation.

Leaders must also deepen engagement with payers and regulatory bodies to establish value-based reimbursement frameworks that reward diagnostic-driven treatment pathways. Investing in real-world evidence generation through longitudinal studies and patient registries will strengthen economic value propositions. On the operational front, optimizing manufacturing footprints via nearshoring or dual sourcing arrangements can offset potential tariff impacts and ensure continuity of critical supplies.

Moreover, integrating artificial intelligence and machine learning into data analysis pipelines will differentiate offerings by delivering actionable insights and predictive capabilities. Embracing digital connectivity to support remote diagnostics and telehealth services will address evolving provider and patient needs. Finally, fostering a culture of continuous learning and cross-functional collaboration within organizations will expedite innovation and enable rapid adaptation to emerging market trends and regulatory changes.

Comprehensive Research Methodology Detailing Data Collection Primary and Secondary Sources Validation Processes and Analytical Frameworks Underpinning Molecular Diagnostics Insights

This research initiative employed a rigorous multi-phase methodology to ensure comprehensive and accurate insights. Primary data was gathered through in-depth interviews with key stakeholders, including laboratory directors, clinical researchers and regulatory experts. These qualitative engagements were complemented by structured surveys targeting decision-makers across hospital and independent laboratory settings, capturing firsthand perspectives on technology adoption, operational challenges and growth priorities.

Secondary research entailed systematic review of peer-reviewed scientific literature, regulatory filings and industry reports to contextualize primary findings within broader market and policy trends. Company press releases, patent filings and financial disclosures provided additional granularity on competitive strategies and innovation trajectories. Data points were triangulated through cross-validation techniques to identify and reconcile discrepancies, ensuring robustness and credibility.

Analytical frameworks incorporated both qualitative thematic analysis and quantitative trend modeling. Segmentation analyses were refined through iterative feedback loops with domain experts, aligning market categorizations with real-world clinical workflows. All findings underwent rigorous peer review and quality assurance checks, verifying the integrity of data inputs and the validity of interpretive conclusions. This methodological rigor underpins the reliability of strategic recommendations and the actionable intelligence presented throughout the report.

Synthesizing Key Insights and Strategic Imperatives to Conclude Molecular Diagnostics Market Trends Innovations Challenges and Pathways for Sustainable Growth and Resilience

In summary, the molecular diagnostics market stands at the cusp of transformative growth, propelled by technological innovations, regulatory evolutions and expanding clinical applications. Strategic segmentation across offerings, technologies, specimen types test formats applications and end users reveals a complex ecosystem where targeted investments and collaborative partnerships are essential to sustainable success. Regional dynamics further underscore the necessity of customized approaches to navigate diverse healthcare infrastructures and policy landscapes.

Competitive positioning will hinge on an organization's ability to integrate advanced analytics, maintain supply chain resilience and demonstrate tangible value through robust clinical and economic evidence. Companies that prioritize agility-balancing centralized laboratory capabilities with decentralized point-of-care solutions-will be well-equipped to address both routine diagnostic demands and emergent public health challenges. Moreover, proactive engagement with regulators and payers will facilitate streamlined approvals and favorable reimbursement pathways.

Ultimately, the path forward requires a harmonious blend of innovation, collaboration and strategic foresight. By leveraging actionable insights into market trends, stakeholders can anticipate shifts, mitigate risks and capitalize on emerging opportunities, thereby driving the next wave of precision medicine advancements and delivering improved patient outcomes worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven analysis platforms to transform high-throughput molecular diagnostics workflows
  • 5.2. Adoption of decentralized next-generation sequencing panels empowering precision medicine in remote healthcare settings
  • 5.3. Emergence of multiplexed liquid biopsy assays enabling noninvasive cancer screening and monitoring capabilities
  • 5.4. Increasing regulatory approvals for companion diagnostics fueling personalized oncology treatment selection globally
  • 5.5. Expanding use of CRISPR-based point-of-care diagnostic assays facilitating rapid pathogen detection
  • 5.6. Advancements in microfluidic lab-on-a-chip platforms to reduce assay volumes and turnaround times for molecular testing
  • 5.7. Rising implementation of digital PCR technologies to enhance sensitivity and quantification accuracy in rare mutation detection

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Molecular Diagnostics Market, by Offering

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software & Services

9. Molecular Diagnostics Market, by Technology

  • 9.1. Fluorescence In Situ Hybridization
  • 9.2. Mass Spectrometry
  • 9.3. Microarray Analysis
  • 9.4. Next-Generation Sequencing
    • 9.4.1. Exome Sequencing
    • 9.4.2. RNA Sequencing
    • 9.4.3. Targeted Sequencing
    • 9.4.4. Whole Genome Sequencing
  • 9.5. Polymerase Chain Reaction
    • 9.5.1. Digital PCR
    • 9.5.2. Multiplex PCR
    • 9.5.3. Real-Time PCR

10. Molecular Diagnostics Market, by Specimen Type

  • 10.1. Blood
  • 10.2. Cerebrospinal Fluid (CSF)
  • 10.3. Nasal/Throat Swabs
  • 10.4. Saliva
  • 10.5. Stool
  • 10.6. Tissue Biopsies
  • 10.7. Urine

11. Molecular Diagnostics Market, by Test Type

  • 11.1. Laboratory Based
    • 11.1.1. Central Lab
    • 11.1.2. Hospital Lab
    • 11.1.3. Independent Lab
  • 11.2. Point Of Care

12. Molecular Diagnostics Market, by Application

  • 12.1. Genetic Testing
    • 12.1.1. Carrier Testing
    • 12.1.2. Diagnostic Testing
    • 12.1.3. Predictive Testing
  • 12.2. Infectious Disease
    • 12.2.1. Bacterial
    • 12.2.2. Parasitic
    • 12.2.3. Viral
  • 12.3. Oncology
    • 12.3.1. Liquid Biopsy
    • 12.3.2. Minimal Residual Disease
    • 12.3.3. Tissue Biopsy
  • 12.4. Prenatal Testing
    • 12.4.1. Invasive
    • 12.4.2. Non-Invasive

13. Molecular Diagnostics Market, by End User

  • 13.1. Academic & Research Institutes
  • 13.2. Diagnostic Laboratories
  • 13.3. Hospitals & Clinics

14. Molecular Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Molecular Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Molecular Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories Inc.
    • 17.3.2. ADT Biotech Co., Ltd.
    • 17.3.3. AstraZeneca plc
    • 17.3.4. Becton, Dickinson, and Company
    • 17.3.5. Bio-Rad Laboratories, Inc.
    • 17.3.6. Biocartis Group NV
    • 17.3.7. bioMerieux SA
    • 17.3.8. Castle Biosciences, Inc.
    • 17.3.9. Danaher Corporation
    • 17.3.10. Diasorin S.p,A.
    • 17.3.11. Exact Sciences Corporation
    • 17.3.12. F. Hoffmann-La Roche AG
    • 17.3.13. Grifols S.A.
    • 17.3.14. Guardant Health, Inc.
    • 17.3.15. Hologic, Inc.
    • 17.3.16. Illumina, Inc.
    • 17.3.17. Laboratory Corporation of America Holdings
    • 17.3.18. Myriad Genetics, Inc.
    • 17.3.19. Oxford Nanopore Technologies
    • 17.3.20. QIAGEN N.V.
    • 17.3.21. Siemens Healthineers AG
    • 17.3.22. Source BioScience
    • 17.3.23. Sysmex Corporation by Oxford Gene Technology
    • 17.3.24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2